The FDA has granted breakthrough therapy designation to ficerafusp alfa (BCA101) in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with metastatic or unresectable/recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors have a PD-L1 combined positive score (CPS) of at least 1, except for human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma.1
The designation is supported by findings from a phase 1/1b trial (NCT04429542), which demonstrated that in patients with HPV-negative, recurrent/metastatic HNSCC with a PD-L1 CPS of at least 1 (n = 28), the combination of ficerafusp alfa and pembrolizumab generated a confirmed objective response rate (ORR) of 54% and an unconfirmed ORR of 64%.2 Findings presented at the 2025 ASCO Annual Meeting also showed that a tumor shrinkage of at least 80% was reported in 80% of confirmed responders (n = 15). The complete response and disease control rates were 21% and 89%, respectively.
Key Highlights for Ficerafusp Alfa in HNSCC
- Ficerafusp alfa is a first-in-class bifunctional antibody that combines an EGFR-directed monoclonal antibody with a TGF-β–binding domain to overcome the fibrotic, immune-excluded tumor microenvironment, enhancing tumor penetration and allowing for deep responses spanning solid tumors.
- In a phase 1/1b trial, first-line ficerafusp alfa plus pembrolizumab produced a confirmed ORR of 54% in patients with HPV-negative, PD-L1–positive, recurrent/metastatic HNSCC.
- The combination of ficerafusp alfa plus pembrolizumab is under further investigation in the phase 2/3 FORTIFI-HN01 trial.
The median time to response with the combination was 1.4 months, and patients achieved a median progression-free survival (PFS) of 9.9 months. The median duration of response (DOR) was 21.7 months, and the 18-month DOR rate was 57%.
At a median follow-up of 25.2 months, the median overall survival (OS) was 21.3 months, and the 2-year OS rate was 46%.
“This [breakthrough therapy] recognition highlights the urgent unmet need for patients with HPV-negative recurrent/metastatic HNSCC,” David Raben, MD, chief medical officer of Bicara Therapeutics, stated in a news release.1 “It also reinforces our conviction that depth and durability of response, driven by ficerafusp alfa's ability to synergize with pembrolizumab and enable tumor penetration, are key to achieving long-term clinical benefit.”
How Was the Phase 1 Investigation of Ficerafusp Alfa Plus Pembrolizumab Designed?
The phase 1/1b trial evaluating ficerafusp alfa as monotherapy and as part of combination therapies for patients with EGFR-driven advanced solid tumors also included an expansion cohort of patients with first-line, recurrent/metastatic, HPV-negative HNSCC who also had a PD-L1 CPS of at least 1.2,3 Patients were allowed to have a primary tumor location of the oropharynx, oral cavity, hypopharynx, or larynx; nasopharynx as a primary tumor location was not permitted.3
In the HNSCC expansion cohort, no prior systemic therapy in the recurrent or metastatic setting was allowed; however, systemic therapy given as part of multimodal treatment in the locally advanced setting was allowed, if completed more than 6 months prior to enrollment. Prior checkpoint inhibitors were allowed only if given in the neoadjuvant setting more than 6 months ahead of study enrollment.